newsfilter
← Earnings
Earnings Releases·

Immunocore — Q3 2026 Earnings Summary

Immunocore reported third-quarter 2026 net revenues of $102.2 million from its lead product KIMMTRAK, bringing year-to-date sales to $324.8 million. The company's Phase 3 TEBE-AM trial for advanced cutaneous melanoma has completed enrollment of 540 patients, with top-line overall survival data expected in the second quarter of 2027. Promising Phase 1 data demonstrated clinical activity and a manageable safety profile for the combination of KIMMTRAK and brenetafusp in metastatic uveal melanoma, prompting plans for a randomized Phase 2/3 DUET-UVEAL trial. Additionally, the first patient was dosed in the Phase 1 trial for IMC-S118AI, the company's first tissue-specific autoimmune candidate for type 1 diabetes.

Company
IMMUNOCORE HOLDINGS PLC
Sector
Healthcare
Industry
Biotechnology